Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)

Richard G Langley, Jeffrey Crowley, Melinda Gooderham, Kim A Papp, Neil J Korman, Lynda Spelman, Atsuyuki Igarashi, Mamitaro Ohtsuki, Aditya K Gupta, Paul Yamauchi, Jeffrey Parno, Alan M Mendelsohn, Stephen J Rozzo, Kimberly Eads

Page s39

Poster PDF

Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in Resurface 1

Wendy Cantrell, Patricia Lee, Alan M Mendelsohn, Jeff Parno, Stephen J Rozzo, Wilson Liao

Page s40

Poster PDF

Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab

Kim A Papp, Jensen Yeung, Neil Shear, Lorne Albrecht, Charles Lynde, Jingchuan Zhang, Yang Zhao, Jeff Parno, Alan M Mendelsohn, Melinda Gooderham

Page s41

Poster PDF

Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies

Mark G Lebwohl, Nehal N Mehta, Alice B Gottlieb, Alan M Mendelsohn

Page s42

Poster PDF

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis

Philip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, Alice B Gottlieb, Richard C Chou, Alan M Mendelsohn, Michael E Luggen

Page s43

Poster PDF

Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

K Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Tha?i, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich

Page s44

Poster PDF

Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)

K Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Tha?i, Y Poulin, M Boehnlein, F Brock, C Arendt, K Reich

Page s45

Poster PDF

Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies

A Blauvelt, C Paul, P van de Kerkhof, R B Warren, A B Gottlieb, R G Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, K Reich

Page s46

Poster PDF

Efficacy of Tapinarof Cream by Body Region in Subjects With Plaque Psoriasis in a Phase 2b Randomized Controlled Study

Robert Bissonnette, Linda Stein Gold, Leon Kircik, Stephen Tyring, Anna Tailman, April Armstrong

Page s47

Poster PDF

Atopic Dermatitis

Dupilumab Improves Symptoms of Anxiety and Depression in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Three Phase 3 Trials (LIBERTY AD SOLO 1 and 2 and ADOL)

Jonathan I Silverberg, Weily Soong, Benjamin Lockshin, Abhijit Gadkari, Zhen Chen, Ashish Bansal

Page s48

Poster PDF

Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)

Eric L Simpson, Hiroyuki Fujita, Kazuhiko Arima, Jennifer Hamilton, Yufang Lu, Ana B Rossi, Ashish Bansal

Page s49

Poster PDF

Long-Term Effect of Dupilumab With Concomitant Topical Corticosteroids on POEM in Adults With Moderate-to-Severe Atopic Dermatitis: LIBERTY AD CHRONOS Trial

Jonathan I Silverberg, Benjamin Lockshin, Melinda Gooderham, Zhen Chen, Abhijit Gadkan, Ana B Rossi

Page s50

Poster PDF

Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis and a History of Allergic Rhinitis: Subgroup Analysis From a Phase 3 Trial (LIBERTY AD ADOL)

Lawrence Sher, Weily Soong, Randy Prescilla, Zhen Chen, Ashish Bansal

Page s51

Poster PDF

Acne & Rosacea

Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials

Angela Moore, Suzanne Bruce, Neil Sadick, Eduardo Tschen, Philip Werschler, Sunil Dhawan, Douglas Farsha, Michael Gold, Scott Guenthner, Steve Kempers, Leon Kircik, Jennifer Parish, Marta Rendon, Phoebe Rich, Linda Stein-Gold, Stephen Tyring, Robert Weiss, Adnan Nasir, Carsten Schmitz, Terry Boodhoo, Alexandre Kaoukhov, David Berk, Fran Cook-Bolden, Ayman Grada

Page s52

Poster PDF

Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris

David M Pariser, Lawrence J Green, Edward L Lain, Carsten Schmitz, Amy S Chinigo, Brian McNames, David R Berk, Jamison Hoffman, Ayman Grada

Page s53

Poster PDF

Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea

Linda Stein Gold, James Q Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart

Page s54

Poster PDF

Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies

James Q Del Rosso, Linda Stein Gold, Leon Kircik, Neal D Bhatia, Neil Sadick, Matthew Zirwas, Edward Lain, Iain Stuart

Page s55

Poster PDF

Effect of Combination Therapy on Visible/Non-Visible Symptoms, and Disease Burden Associated with Severe Rosacea: Results from A Post-Hoc Analysis of A Randomized Controlled Trial

James Q Del Rosso, Mark Jackson, Sandra Johnson, Alison Harvey, Rajeev Chavda

Page s56

Poster PDF

Trifarotene 50 µg/G Cream for Treatment of Acne Vulgaris – A Summary of Two Randomized Trials and a Long-Term Safety Study

Jerry Tan, James Del Rosso, Jonathan Weiss, Linda Stein Gold, Fran Cook-Bolden, Lawrence Eichenfeld, Emil Tanghetti, Alessandra Ali? Saenz, Faiz Ahmad

Page s57

Poster PDF